Further, we tested several BTK/BMX inhibitors, with HPLC analyses showing that zanubrutinib or ibrutinib treatment significantly decreased DHEA metabolism in multiple prostate cancer (LNCaP, C4-2, and VCaP) cell lines (Figure 2A and Supplemental Figure 2, B–D). Here, BMX is linked to prostate cancer.